GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to
evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with
HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed
on prior endocrine therapy.